

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		Application Number		10679699	
		Filing Date		2003-10-02	
		First Named Inventor		David Bar-Or	
		Art Unit		1649	
		Examiner Name		Gregory Emch	
		Attorney Docket Number		4172-85	

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
/G.E./	1	6358957		2002-03-19	Fukumoto et al.	
	2	6635649		2003-10-21	Teng et al.	
↓	3	7026322		2006-04-11	Hayashi et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
/G.E./	1	20040132738		2004-07-08	Teng et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS						Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
/G.E./	1	2000-2680	CZ		2000-07-21	Kasafirek et al.		<input checked="" type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10679699
Filing Date	2003-10-02
First Named Inventor	David Bar-Or
Art Unit	1649
Examiner Name	Gregory Emch
Attorney Docket Number	4172-85

/G.E./	2	2000-2681	CZ		2000-07-21	Kasafirek et al.		<input checked="" type="checkbox"/>
	3	2827.94	CZ		1996-04-17	Galena		<input checked="" type="checkbox"/>
	4	01013075	JP		1989-01-17	Nippon Chemiphar Co LTD		<input checked="" type="checkbox"/>
	5	08277203	JP		1996-10-22	Kaiyo Bio Technol Kenkyusho:KK Shizuoka Prefecture		<input checked="" type="checkbox"/>
	6	59-73574	JP		1984-04-25	Grelan Pharmaceutical Co., Ltd.		<input checked="" type="checkbox"/>
	7	2004/054498	WO		2004-07-01	Nereus Pharmaceuticals, Inc.		<input type="checkbox"/>
↓	8	2005/011699	WO		2005-02-10	Nereus Pharmaceuticals, Inc.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
/G.E./	1	Weng et al., " Novel CCK-B receptor agonists: diketopiperazine analogues derived for CCK4 bioactive conformation" Regul Pept, August 27, 1996; Vol. 65(1); Abstract only	<input type="checkbox"/>
/G.E./	2	Battersby et al., "Diketopiperazine formation and N-terminal degradation in recombinant human growth hormone", Int J Pept Protein Res., September 1994; Vol 44(3); Abstract only	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10679699
Filing Date	2003-10-02
First Named Inventor	David Bar-Or
Art Unit	1649
Examiner Name	Gregory Emch
Attorney Docket Number	4172-85

/G.E./	3	Lee et al., "Cyclo (Leu-Gly attenuates the striatal dopaminergic supersensitivity induced by chronic morphine.", Alcohol Drugs Res.; 1987; Vol. 7(1); Abstract only	<input type="checkbox"/>
	4	Bressan et al. " Coordination chemistry of peptides. Part II. Crystal structure of cyclo-L-methionylglycine and studies of metal complexation", Int J Pept Protein Res; April 1982; Vol 19(4); Abstract only	<input type="checkbox"/>
	5	Suzuki et al., "Effect of cyclic dipeptides containing histidine on pentobarbital narcosis", J Pharmacobiodyn; May 1981; Vol 4(5); Abstract only	<input type="checkbox"/>
	6	Jara et al., "Elevated serum levels of cyclo (His-Pro), and endogenous inhibitor of pituitary prolactin secretion, in systemic lupus erythematosus patients.", Lupus; 1997; Vol 6(3); Abstract only	<input type="checkbox"/>
	7	Woehlecke et al., "Reversal of breast cancer resistance protein-mediated drug resistance by tryprostatin A.", Int J Cancer; December 10, 2003; Vol. 107(5); Abstract only	<input type="checkbox"/>
	8	"Tryprostatin A, Aspergillus fumigatus"; available at http://www.emdbiosciences.com/Products/ProductDisplay.asp?catno=649305& ; printed on June 21, 2006, 1 page	<input type="checkbox"/>
	9	Caballero et al., "Brief total synthesis of the cell cycle inhibitor tryprostatin B and related preparation of its alanine analogue.", J Org Chem.; September 5, 2003; Vol 68(18); Abstract only	<input type="checkbox"/>
	10	Caballero et al., "Brief synthesis of the cell cycle inhibitor tryprostatin B and its alanine analogue.", Fourth International Electronic conference of Synthetic Organic Chemistry (ECXOC-4), September 1-13, 2000, 4 pages, available at http://pages.unibas.ch/mdpi/eecxoc-4/c0023/c0023.htm .	<input type="checkbox"/>
	11	Goolcharran et al. " Comparison of the rates of deamidation, diketopiperazine formation and oxidation in recombinant human vascular endothelial growth factor and model peptides." AAPS PharmSci., 2000; Vol 2(1); Abstract only	<input type="checkbox"/>
	12	Houston et al., " The cyclic dipeptide Cl-4 [cyclo-(I-Arg-d-Pro)] inhibits family 18 chitinases by structural mimicry of a reaction intermediate.", Biochem J.; November 15, 2002; Vol 368(Pt 1); Abstract only	<input type="checkbox"/>
↓	13	Jamie et al., "The effect of the isomers of cyclo(Trp-Pro) on heart and ion-channel activity." J Pharm Pharmacol; December 2002; Vol. 54(12); Abstract only	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10679699
Filing Date	2003-10-02
First Named Inventor	David Bar-Or
Art Unit	1649
Examiner Name	Gregory Emch
Attorney Docket Number	4172-85

/G.E./	14	Strom et al., "Lactobacillus plantarum MiLAB 393 produces the antifungal cyclic dipeptides cyclo(L-Phe-L-Pro) and cyclo(L-Phe-trans-4-OH-L-Pro) and 3-phenyllactic acid.", Appl Environ Microbiol; September 2002; Vol. 68(9); Abstract only	<input type="checkbox"/>
	15	Serdenin et al. " Endogenous dipeptide cycloprolylglycine shows selective anxiolytic activity in animals with manifest fear reaction", Bull Exp Biol Med; April 2002; Vol 1333(4); Abstract only	<input type="checkbox"/>
	16	Ostrovskaya et al., "Multicomponent antithrombotic effect of the neuroprotective prolyl dipeptide GVS-111 and its major metabolite cyclo-L-prolylglycine", Eksp Klin Farmakol; Mar-Apr 2002; Vol 65(2); Abstract only	<input type="checkbox"/>
	17	Edhila et al., "dd-diketopiperazines: antibiotics active against Vibrio anguillarum isolated from marine bacteria associated with cultures of Pecten maximus." J Nat Prod; October 2003; Vol 66(10); Abstract only	<input type="checkbox"/>
	18	Moldavkin et al., "[Effect of the novel dipeptide nootropic agent noopept and its metabolite cyclo-L-prolylglycine on the transcallosal evoked potential in the rat brain]", Eksp Klin Farmakol; Mar-Apr 2002; Vol 65(2); Abstract only	<input type="checkbox"/>
	19	Gudasheva et al., "Anxiolytic activity of endogenous nootropic dipeptide cycloprolylglycine in elevated plus-maze test" Bull Exp Biol Med; May 2001; Vol 131(5); Abstract only	<input type="checkbox"/>
	20	Liu et al., "Hydroxyprolylserine derivatives JBP923 and JBP485 exhibit the antihepatitis activities after gastrointestinal absorption in rats." J Pharmacol Exp Ther; Aug 2000; Vol. 294(2); Abstract only	<input type="checkbox"/>
	21	Gudasheva et al. "Identification of a novel endogenous memory facilitating cyclic dipeptide cyclo-prolylglycine in rat brain" FEBS Lett; August 5, 1996; Vol 391(1-2); Abstract only	<input type="checkbox"/>
	22	Lindner et al., "[Effects of cyclic adenosine-3',5'-monophosphate and cyclo(Lys-Pro).HCl neuronotrophic factors in tissue culture]", J Hirnforsch, 1987; Vol 28(3); Abstract only	<input type="checkbox"/>
	23	Sato et al., "Comparison of the anticonvulsive effect between the cyclic dipeptide cyclo[Tyr(Et)-homoarginine] and the linear dipeptide Boc-Tyr(Et)-homoarginine-Orn in rats.", Jpn J Pharmacol; Jan 1984; Vol. 34(1); Abstract only	<input type="checkbox"/>
↓	24	Bhargava, "The effect of melanotrophin release inhibiting factor (MIF) and cyclo (Leu-Gly) on the tolerance to morphine-induced antinociception in the rat: a dose-response study", Br J Pharmacol, Apr 1981; 72(4); Abstract only	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10679699
Filing Date	2003-10-02
First Named Inventor	David Bar-Or
Art Unit	1649
Examiner Name	Gregory Emch
Attorney Docket Number	4172-85

/G.E./	25	Rainbow et al., "Distribution, survival and biological effects in mice of a behaviorally active, enzymatically stable peptide: pharmacokinetics of cyclo(Leu-Gly) and puromycin-induced amnesia" <i>Pharmacol Biochem Behav.</i> ; May 1979; Vol 10(5); Abstract only	<input type="checkbox"/>
	26	Cui et al., "Novel Mammalian Cell Cycle Inhibitors, Tryprostatins A, B and Other Diketopiperazines Produced by <i>Aspergillus fumigatus</i> II. Physico-chemical properties and Structures", <i>The Journal Of Antibiotics</i> , June 1996, p. 534-540	<input type="checkbox"/>
	27	Graz et al. "Mechanism of a anti-fungal action of selected cyclic dipeptides", <i>Pharmazie</i> ; Nov 2001; Vol. 56(11); p. 900-1	<input type="checkbox"/>
	28	Graz et al "Cyclic Dipeptides in the Induction of Maturation for Cancer Therapy", <i>J. Pharm. Pharmacol.</i> 2000; Vol 52; p. 75-82	<input type="checkbox"/>
	29	Degrassi et al., "Plant Growth-Promoting <i>Pseudomonas putida</i> WCS358 Produces and Secretes Four Cyclic Dipeptides: Cross-Talk with Quorum Sensing Bacterial Sensors", <i>Current Microbiology</i> ; 2002; Vol 45; p. 250-254	<input type="checkbox"/>
	30	Holden et al. "Quorum-sensing cross talk: isolation and chemical characterization of cyclic dipeptides from <i>Pseudomonas aeruginosa</i> and other Gram-negative bacteria"; <i>Molecular Microbiology</i> ; 1999; Vol 33(6); p. 1254-1266	<input type="checkbox"/>
	31	Wretlind "The Availability of the Isopropyl Ester of L- and D-Phenylalanine and 3,6-Dibenzyl-2,5-Diketopiperazine form Growth in Rats", <i>Acta phys. Scandinav.</i> May 26, 1953, Vol. 30, p. 97-104	<input type="checkbox"/>
	32	Walter et al., "The Cyclized C-Terminal Dipeptide of Arginine Vasopressin: Metabolic Stability and Antagonism of Puromycin-Induced Amnesia", <i>Hormones and Behavior</i> , 1982; Vol 16; p. 234-244	<input type="checkbox"/>
	33	Mizuma et al., "Intestinal Absorption of Stable Cyclic Glycylphenylalanine: Comparison with the Linear Form", <i>J. Pharm. Pharmacol.</i> ; 1997; Vol 49; p. 1067-1071	<input type="checkbox"/>
	34	Hlinak et al., "Effect of alaptide, its analogues and oxiracetam on memory for an elevated plus-maze in mice", <i>European Journal of Pharmacology</i> ; 1996; Vol 314; p. 1-7	<input type="checkbox"/>
↓	35	Mizuma et al., "Concentration-Dependent Preferences of Absorptive and Excretive Transport Cause Atypical Intestinal Absorption of Cyclic Phenylalanylserine: Small Intestine Acts as an Interface Between the Body and Ingested Compounds", <i>Research Communications in Molecular Pathology and Pharmacology</i> , 2002, Vol. 111, p. 199-209	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10679699
Filing Date	2003-10-02
First Named Inventor	David Bar-Or
Art Unit	1649
Examiner Name	Gregory Emch
Attorney Docket Number	4172-85

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Gregory Emch/	Date Considered	05/15/2007
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.